↓ Skip to main content
Embed badge What is this page?

Age-Dependent Seroprevalence of JCV Antibody in Children

Overview of attention for article published in Neuropediatrics, October 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#16 of 434)
  • High Attention Score compared to outputs of the same age (83rd percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

blogs
1 blog
twitter
1 tweeter

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
16 Mendeley

What is this page?

Summary Blogs Twitter Dimensions citations
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Age-Dependent Seroprevalence of JCV Antibody in Children
Published in
Neuropediatrics, October 2015
DOI 10.1055/s-0035-1565272
Pubmed ID
26479766
Authors

Eva Hennes, Barbara Kornek, Peter Huppke, Markus Reindl, Kevin Rostasy, Thomas Berger

Abstract

Progressive multifocal leukoencephalopathy (PML) is an opportunistic central nervous system infection, caused by the John Cunningham virus (JCV). PML may occur during treatment with immunosuppressive agents or monoclonal antibodies such as natalizumab. The JCV seroprevalence increases with age with a seropositivity of 60% in the adult human population. In this study, we analyzed sera from 109 pediatric multiple sclerosis (MS) patients (mean age 14 years) as well as sera from 162 patients with a wide range of suspected neurologic disorders (mean age 6.3 years). Our results showed a considerably lower seroprevalence for JCV in our pediatric cohort with 33.3% and equal distribution in both subgroups, compared with reported seropositivity in adult population. This could result in a lower risk for drug-induced PML in pediatric patients compared with adult patients and can influence the indication for natalizumab therapy in pediatric MS patients.

View on publisher site

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 16 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 5 31%
Professor > Associate Professor 2 13%
Student > Doctoral Student 2 13%
Student > Master 2 13%
Student > Bachelor 1 6%
Other 3 19%
Unknown 1 6%
Readers by discipline Count As %
Medicine and Dentistry 11 69%
Neuroscience 2 13%
Immunology and Microbiology 1 6%
Unknown 2 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 October 2015.
All research outputs
#1,639,521
of 12,359,775 outputs
Outputs from Neuropediatrics
#16
of 434 outputs
Outputs of similar age
#42,973
of 264,389 outputs
Outputs of similar age from Neuropediatrics
#1
of 14 outputs
Altmetric has tracked 12,359,775 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 434 research outputs from this source. They receive a mean Attention Score of 2.5. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,389 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.

This page is provided by Altmetric.